Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.

Autor:	Guberina M; Department of Radiotherapy, West German Cancer Center, University Hospital Essen, Essen, 45147, Germany.; German Cancer Consortium, Partner Site University Hospital Essen, Essen, 45147, Germany., Guberina N; Department of Radiotherapy, West German Cancer Center, University Hospital Essen, Essen, 45147, Germany., Pöttgen C; Department of Radiotherapy, West German Cancer Center, University Hospital Essen, Essen, 45147, Germany., Gauler T; Department of Radiotherapy, West German Cancer Center, University Hospital Essen, Essen, 45147, Germany., Richlitzki C; Department of Radiotherapy, West German Cancer Center, University Hospital Essen, Essen, 45147, Germany., Metzenmacher M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, 45147, Germany.; Division of Thoracic Oncology, University Medicine Essen-Ruhrlandklinik, Essen, 45239, Germany., Wiesweg M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, 45147, Germany.; Division of Thoracic Oncology, University Medicine Essen-Ruhrlandklinik, Essen, 45239, Germany., Plönes T; Department of Thoracic Surgery and Endoscopy, University Medicine Essen-Ruhrlandklinik, West German Cancer Center, University Hospital Essen, Essen, 45239, Germany., Forsting M; Institute of Diagnostic, Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, 45147, Germany., Wetter A; Institute of Diagnostic, Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, 45147, Germany., Herrmann K; German Cancer Consortium, Partner Site University Hospital Essen, Essen, 45147, Germany.; Department of Nuclear Medicine, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, 45147, Germany., Hautzel H; German Cancer Consortium, Partner Site University Hospital Essen, Essen, 45147, Germany.; Department of Nuclear Medicine, University Hospital Essen, West German Cancer Center, University Duisburg-Essen, Essen, 45147, Germany., Darwiche K; Department of Pulmonary Medicine, Section of Interventional Pneumology, University Medicine Essen-Ruhrlandklinik, Essen, 45239, Germany., Theegarten D; Institute of Pathology, University Hospital Essen, Essen, 45147, Germany., Aigner C; German Cancer Consortium, Partner Site University Hospital Essen, Essen, 45147, Germany.; Department of Thoracic Surgery and Endoscopy, University Medicine Essen-Ruhrlandklinik, West German Cancer Center, University Hospital Essen, Essen, 45239, Germany., Schuler M; German Cancer Consortium, Partner Site University Hospital Essen, Essen, 45147, Germany.; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, 45147, Germany.; Division of Thoracic Oncology, University Medicine Essen-Ruhrlandklinik, Essen, 45239, Germany., Stuschke M; German Cancer Consortium, Partner Site University Hospital Essen, Essen, 45147, Germany., Eberhardt WE; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, 45147, Germany.; Division of Thoracic Oncology, University Medicine Essen-Ruhrlandklinik, Essen, 45239, Germany.
Jazyk:	angličtina
Zdroj:	Immunotherapy [Immunotherapy] 2022 Aug; Vol. 14 (12), pp. 927-944. Date of Electronic Publication: 2022 Jul 13.
DOI:	10.2217/imt-2021-0341
Abstrakt:	The pivotal PACIFIC trial defined durvalumab consolidation as the new standard of care in patients with stage III non-small-cell lung cancer treated with definitive radiochemotherapy. The authors characterized the durvalumab effect after induction chemotherapy according to the ESPATUE trial and definitive radiochemotherapy. All consecutive patients with stage III non-small-cell lung cancer receiving definitive radiochemotherapy between January 2017 and February 2020 were included. Primary end points were progression-free survival and overall survival. Altogether, 160 patients (75 PD-L1-positive, 62 PD-L1-negative, 23 unknown) received definitive radiochemotherapy, 146 (91%) of whom received prior induction chemotherapy. Durvalumab consolidation showed high effectiveness overall and in the good-risk group according to the PACIFIC trial (log-rank test: p < 0.005). Hazard ratios for progression-free survival and overall survival were at the lower limits of those in the PACIFIC trial. These results were robust to adjustment for potential confounders by propensity score weighting. Eastern Cooperative Oncology Group (ECOG) performance status was the most important pretreatment prognostic factor.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu